SCHEMBL2407261

SCHEMBL2407261

FC(F)(F)c1[c]nc2ccccc2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.40
KDM4E B2RXH2 4/20 0.39
NPSR1 Q6W5P4 2/20 0.37
GAA P10253 4/20 0.37
ALDH1A1 P00352 3/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
BACE1 P56817 1/20 0.34
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 2/20 0.33
CYP2C19 P33261 2/20 0.33
NQO2 P16083 2/20 0.33
ELANE P08246 1/20 0.33
PKM P14618 1/20 0.33
HRH4 Q9H3N8 1/20 0.33
KHK P50053 1/20 0.33
MAPK1 P28482 1/20 0.32
MEN1 O00255 1/20 0.32
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2302808 0.79 MAPT (0.40) MAPTKDM4EGAAALDH1A1HPGD
SCHEMBL9480318 0.73 MAPT (0.48) MAPTKDM4EGAAALDH1A1HPGD
SCHEMBL6980664 0.69 MAPT (0.38) MAPTKDM4ENPSR1GAAALDH1A1
SCHEMBL5250342 0.68 MAPT (0.41) MAPTKDM4ENPSR1GAAALDH1A1
SCHEMBL30753427 0.67 MAPT (0.63) MAPTKDM4ENPSR1GAAALDH1A1
SCHEMBL13641617 0.67 MAPT (0.63) MAPTKDM4ENPSR1GAAALDH1A1
SCHEMBL9479792 0.67 MAPT (0.46) MAPTKDM4EGAAALDH1A1HPGD
SCHEMBL558407 0.67 TDP1 (0.50) MAPTKDM4EGAAALDH1A1HPGD
SCHEMBL315192 0.67 MAPT (0.46) MAPTKDM4ENPSR1GAAALDH1A1
SCHEMBL9481868 0.67 MAPT (0.46) MAPTKDM4ENPSR1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4017591-A1 ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES UCB Biopharma SRL (BE) 2022-06-29 EP disclosed
CN-114206856-A Anti-malarial hexahydropyrimidine analogues UCB生物制药有限责任公司 2022-03-18 CN disclosed
WO-2021032687-A1 ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES UCB Biopharma SRL (BE) 2021-02-25 WO disclosed
EP-2539342-B1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2015-04-15 EP disclosed
US-8969376-B2 Pyrazolopyrimidine compounds and their use as PDE10 inhibitors MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-03-03 US disclosed
EP-2539342-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS Mitsubishi Tanabe Pharma Corporation (JP) 2013-01-02 EP disclosed
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-12-06 US disclosed
WO-2011105628-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309754-A1 PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS PDE3B, PDE3A, PDE5A MAPT 4404/4885KDM4E 408/4885NPSR1 2131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.